Home
Array BioPharma

Array BioPharma Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainarraybiopharma.com

Year Founded1998

Employees51 - 200

Annual Revenue$200M - $500M

Array BioPharma

Array BioPharma (including company regionals)

arraybiopharma.com

See more website traffic and engagement information

Array BioPharma Revenue up to November 2025 is 200M - 500M

revenue generated by Array BioPharma top domains

Array BioPharma top domains revenue over 3 years

Revenue for Array BioPharma top domains

arraybiopharma.com200M - 500M

See more with Sales Intelligence

Total visits to Array BioPharma's top domains

Understand Array BioPharma market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Array BioPharma's top domains

Analyze Array BioPharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Array BioPharma's top domains

See how Array BioPharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Array BioPharma top competitors by domain

Top similar sites in November 2025, ranked by their affinity

clovisoncology.comCompany NameClovis OncologyEmployees201 - 500HQUnited States, Colorado, BoulderAnnual revenue$100M - $200MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Array BioPharma

These are the website technologies, by industry, used by Array BioPharma top domains

Advertising (15)

DoubleClick

Social (8)

Instagram

Conversion & Analytics (5)

Google Analytics

Audio Video Media (3)

YouTube

More Technologies

8

See all

News & Signals from Array BioPharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArraybiopharma increases headcount by 100.The 22-acre expansion will allow Array to hire nearly 100 new employees over the next several years.

NewsArraybiopharma is developing ARRY-380 on May 30th '21.Oncothyreon Inc. (NASDAQ: ONTY ) and Array BioPharma Inc. (NASDAQ: ARRY ) today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

NewsThomas left Arraybiopharma as Vice President of Clinical Development of the company’s oncology division on Apr 11th '20.Dr. Thomas joins Caribou from Array Biopharma where she most recently served as Vice President of Clinical Development of the company’s oncology division.